Sarcoidosis, small fiber neuropathy and disability: Living with an invisible disease

Introduction

Sarcoidosis is a systemic inflammatory disease of unknown cause that can affect almost any organ in the body, most commonly the lungs, lymph nodes, skin, eyes and nervous system. One of its more serious but less recognised complications is small fiber neuropathy (SFN), a peripheral nerve disorder that can cause chronic pain, sensory and autonomic dysfunction, and considerable difficulty moving.

Because symptoms often do not show up on standard medical tests, people with this type of neuropathy frequently encounter misunderstandings within the medical community and lengthy processes to document disability. This article describes sarcoidosis, small fiber neuropathy, movement difficulties and the challenges of disability recognition.

What is small fiber neuropathy?

Small fiber neuropathy (SFN) is a form of peripheral neuropathy affecting unmyelinated and thinly myelinated fibers in the somatic and autonomic nervous systems. These fibers are responsible for pain and temperature sensation and for autonomic functions such as blood pressure regulation, heart function, sweating and digestion.

Symptoms of SFN include:

Neuropathic pain: burning, tingling, prickling or electric-shock sensations.

Sensory changes: reduced or increased sensitivity to temperature and pain, or a feeling as though the feet are “wrapped in cotton”.

Autonomic nervous system disturbances: problems with sweating, blood pressure, heart function, digestion or urination.

Extreme fatigue, which can be exhausting and prevent normal functioning.

Difficulty moving because of pain, weakness and loss of sensation.

In the context of sarcoidosis, small fiber neuropathy may arise from an autoimmune response and chronic inflammation, resulting in nerve damage and reduced nerve function.

How does sarcoidosis lead to small fiber neuropathy?

Although the exact mechanism is not yet fully understood, research suggests several possible causes:

1. Granulomas and nerve damage: Sarcoidosis causes granulomas, or inflammatory clusters, to accumulate in different tissues, including the nervous system. These granulomas can directly damage peripheral nerves, including small nerve fibers.

2. Autoimmune response: Sarcoidosis is described here as a disease in which the immune system attacks the body’s own tissues, potentially leading to an autoimmune attack on nerves.

3. Inflammatory cytokines: Inflammation can cause an imbalance in chemical signals that affect nerve cells, leading to pain and dysfunction.

4. Autonomic nervous system dysfunction: Small-fiber damage can disrupt autonomic functions, further worsening symptoms.

Difficulties with movement and everyday functioning

Small fiber neuropathy can seriously affect the ability to move and carry out everyday activities. Patients often face a combination of pain, weakness and sensory disturbances, which can lead to:

1. Limited mobility because of pain

Intense neuropathic pain in the feet and legs can prevent normal walking.

Pain can also occur at rest, further limiting mobility.

2. Weakness and loss of coordination

Small-fiber damage can cause a feeling of unsteadiness when walking, as though the legs “do not obey”.

Patients often have balance difficulties, increasing the risk of falls.

Muscles may become weak and stiff, particularly after prolonged sitting or rest.

3. Loss of sensation in the feet and hands

Patients may have difficulty walking on uneven ground because they do not feel the surface properly.

Reduced sensation can increase the risk of injury because heat, cold or pressure on the skin may not be felt.

4. Fatigue and exhaustion

Chronic pain and autonomic dysfunction can cause persistent fatigue, which can be as disabling as the neurological symptoms themselves.

Fatigue makes basic activities such as climbing stairs, standing for long periods or driving more difficult.

Disability recognition in sarcoidosis and small fiber neuropathy

Because symptoms are often invisible and difficult to measure with standard medical tests, disability recognition can be challenging for people with sarcoidosis and SFN.

1. Documenting the diagnosis

To support disability recognition, detailed medical documentation needs to be collected, including:

Neurological examinations: although standard EMG and nerve conduction studies (ENG) often show no damage, a skin biopsy may confirm a reduction in small nerve fibers.

Quantitative sensory testing (QST), which may show reduced temperature and pain sensation.

Autonomic tests, including measurements of sweating, heart rate variability and blood pressure.

2. Functional assessment of disability

Alongside medical records, assessment considers a person’s ability to:

Carry out everyday activities such as cooking, dressing and personal hygiene.

Move independently and maintain balance.

Sit, stand and walk for prolonged periods.

3. Psychological aspects of disability

Chronic pain and fatigue often lead to anxiety and depression, further reducing quality of life.

Psychological findings can play an important role in disability recognition.

Conclusion

Sarcoidosis and small fiber neuropathy can substantially reduce quality of life through chronic pain, movement difficulties, fatigue and autonomic dysfunction. Disability recognition is often a lengthy and demanding process, but appropriate medical documentation and functional assessment can help patients obtain suitable support and benefits.

If you have symptoms of small fiber neuropathy or sarcoidosis, it is important to consult specialists for an appropriate diagnosis, treatment and support with disability recognition.

Dino-Josip Ključarić

Sarcoidosis and Small Fiber Neuropathy (SFN)

Wondering why sarcoidosis can cause so much joint pain even when arthritis is not present?

The following discussion comes from the scientific review cited below, published in 2012, which explores the causes of pain.

Sarcoidosis and pain caused by small fiber neuropathy

Sarcoidosis is a chronic inflammatory disease, and small fiber neuropathy (SFN) is one of its disabling and often chronic manifestations. SFN causes peripheral pain and symptoms of autonomic dysfunction. Pain can be burning or shooting; allodynia and hyperesthesia may also occur. Diagnosis is generally based on clinical features combined with abnormal specialised tests. Treatment often aims to reduce pain, although complete relief is rarely achieved. The role of TNF-α in the pathogenesis of SFN in sarcoidosis is of research interest. The 2012 review also identifies agents such as ARA 290, a non-haematopoietic erythropoietin analogue with potent anti-inflammatory and tissue-protective properties, as candidates for investigation in sarcoidosis-associated SFN.

Small fiber neuropathy

Small fiber neuropathy (SFN) is a peripheral nerve disorder selectively affecting thinly myelinated Aδ fibers and unmyelinated C fibers. Small nerve fibers have both somatic and autonomic functions. Consequently, patients may experience neuropathic pain (NP) and autonomic dysfunction.

Damage to or loss of small somatic nerve fibers causes burning pain, tingling or numbness, usually affecting the limbs in a distal-to-proximal pattern. Symptoms are generally worse at night and often disturb sleep. Some people sleep with their legs uncovered because they cannot tolerate contact with bed sheets. Walking may also be difficult because pressure against the floor is painful. When autonomic fibers are involved, patients may experience dry eyes, dry mouth, orthostatic dizziness, constipation, bladder incontinence, sexual dysfunction, excessive or reduced sweating, or red or white skin discolouration. Restless legs syndrome may also occur, with unpleasant sensations in the legs, typically before falling asleep, and an almost irresistible urge to move.

Most patients have length-dependent small fiber sensory neuropathy (LD-SFSN): symptoms and signs begin in the toes and feet, then gradually progress to the distal legs, fingertips and hands. Non-length-dependent small fiber sensory neuropathy (NLD-SFSN) is less common and causes symptoms in a patchy distribution. The face, upper limbs or trunk may be affected before the lower limbs. NLD-SFSN occurs more often in women and begins at a younger age.

Symptoms of small fiber neuropathy

Sensory symptoms

Pain; paresthesias; intolerance of contact with bed sheets; restless legs syndrome.

Symptoms of autonomic dysfunction: reduced or excessive sweating.

Diarrhoea or constipation; urinary incontinence or retention; gastroparesis; sicca syndrome; blurred vision; facial flushing; orthostatic intolerance; sexual dysfunction.

Diagnosis of small fiber neuropathy

The cited 2012 review explains that nerve conduction studies, which are central to evaluating other, large-fiber neuropathies, are generally normal in SFN. The contrast between severe pain and a lack of neurological or electrophysiological findings therefore made the syndrome puzzling to clinicians. Advances in diagnostic techniques help provide objective support for a clinical diagnosis and characterise the fibers involved. The review notes that a diagnostic gold standard was not available. Diagnosis is generally based on clinical features combined with abnormal specialised tests, including intraepidermal nerve fiber density (IENFD) in a skin biopsy, temperature sensation tests, and sudomotor and cardiovagal tests for autonomic fibers. All tests have limitations.

Quantitative sensory testing (QST) includes assessment of the temperature threshold. Thermal (cold and warm) and mechanical (tactile and vibration) detection thresholds assess small-fiber function, including central pathways. The cold detection threshold (CDT) assesses A-delta fiber function, while C-fiber function is assessed using the warm detection threshold (WDT). The main limitation of QST is its psychophysical nature. As a result, response bias, including deliberate simulation of symptoms, and other non-organic factors may affect test results.

Laser-evoked potentials (LEPs) and contact heat-evoked potentials (CHEPs) have been developed for objective assessment of small nerve fibers. Both laser and contact heat stimulation are well established to activate thermo-nociceptive cutaneous nerves. Although attention and other cognitive processes affect the amplitude of LEPs and CHEPs, these tests provide relevant information about the functional status of nociceptive terminals.

In the specialist laboratory method described in the cited review, CHEPs use a thermofoil thermode stimulator to reach 53 °C at a rate of 70 °C/s. Patients with sensory neuropathy were shown to have lower CHEP amplitudes, correlating with other SFN tests.

Several studies have emphasised the importance of assessing intraepidermal nerve fiber density (IENFD) using PGP-9.5 immunofluorescent staining in a skin biopsy when evaluating SFN.

Epidermal nerves are the distal endings of small dorsal root ganglion neurons that cross the dermal–epidermal basement membrane and enter the epidermis. The discovery of antibodies to the neuropeptide protein gene product (PGP) enabled effective staining of nerve fibers.

Treatment: historical sarcoidosis context

The cited 2012 review describes corticosteroids as the mainstay of sarcoidosis treatment, although alternatives were often used. It reports historical use in chronic, resistant sarcoidosis of immunosuppressive agents (chlorambucil, cyclophosphamide, methotrexate, ciclosporin and azathioprine), anticytokine agents (thalidomide and pentoxifylline), antimalarials (chloroquine and hydroxychloroquine), melatonin and monoclonal antibodies (infliximab). This list concerns sarcoidosis in general; it is not a claim that all these agents are effective treatments for SFN.

SFN is disabling, and its pain is often difficult to treat. It has a major impact on quality of life and can cause disability.

Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3523152/

Rating: 0 stars, 0 votes.